Beta-Amyloid (1-42), Total and Phosphorylated Tau Protein Levels in Cerebrospinal Fluids of Patients with Multiple Sclerosis and Alzheimer’s Disease

Objective: In this study, we wished to investigate the levels of cystatin C, Amyloid beta 42 (Aβ42), total and phosphoryl-ated tau protein in patients with Multiple Sclerosis (MS) and Alzheimer’s disease (AD) in cerebrospinal fluids (CSF); their usefulness in diagnosis and prognosis. Methods: In this study, four patients with AD in the study group, eight patients in the control group, for multiple scle-rosis, 14 patients in the study group and 13 patients in the control group were included. Aβ42, total tau protein and phosphorylated tau protein were analysed by the ELISA method; cystatin C was analysed by the turbidimetric method. Results: No statistically significant difference was detected between study and control groups of Alzheimer’s disease in total and phosforylated tau protein, Aβ42 and cystatin C levels (p>0.05). Additionally, no statistically significant dif-ference between study and control groups of MS in total and phosforylated tau protein, cystatin C levels (p>0.05) was detected. However, the Aβ42 level was lower, total tau protein/Ab42 was higher in the study group of MS patients (p<0.001). Aβ42, total and phosphorylated tau protein and cystatin-C level in CSF of AD and MS patients are not useful markers that can be used in diagnosis and prognosis. Total tau protein / Aβ42 is higher in the study group of MS com-pared to the control group. Conclusion: Measurement of Aβ42 levels and total tau protein / Aβ42 values may be considered as diagnostic and prog